A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Recruiting now Phase 1/2 NCT06730750
Run by Bristol-Myers Squibb · for 18 and older · All sexes
What this study is about
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Who can join (things the study team will check)
✅ You may be able to join if…
- Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.
- CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B: i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma histology and whose disease has progressed after systemic cancer therapy in the metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if available and not contraindicated).
- NSCLC: Part 2A-NSCLC/GC, 2L+ NSCLC: i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV, or recurrent disease. ii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if available.
- GC: Part 2A-NSCLC/GC, 2L+ GC: i) Participants must have received and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (or have progressed within 6 months of adjuvant therapy). ii) ECOG performance status of 0 or 1.
🚫 You may not be able to join if…
- History of anaphylactic reactions to irinotecan and/or bevacizumab.
- Previously received therapy targeting CEACAM5.
- Grade ≥3 ILD/pneumonitis.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where this trial is running
- Local Institution - 0007, Los Angeles, California, United States
- Local Institution - 0017, Grand Rapids, Michigan, United States
- Local Institution - 0004, Hackensack, New Jersey, United States
- Local Institution - 0006, Pittsburgh, Pennsylvania, United States
- Tasman Oncology Research, Southport, Queensland, Australia
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06730750.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.